Last updated: February 17, 2026
What is the current market landscape for drug NDC: 69230-0326?
NDC 69230-0326 corresponds to Olanzapine + Fluoxetine combination therapy, marketed under the brand name Symbyax. It is approved for treatment-resistant depression, bipolar disorder, and other psychiatric conditions. The drug blend combines olanzapine, an atypical antipsychotic, with fluoxetine, a selective serotonin reuptake inhibitor (SSRI).
The drug occupies a niche in the psychiatric therapeutics market with established competition from other mood stabilizers, antipsychotics, and antidepressants. Symbyax's positioning depends on the efficacy for resistant cases, clinical guidelines, and insurance coverage.
What is the current market size and sales trend?
Market Size & Sales Data:
- Global Sales (2022): Approximately $600 million, representing a decline from peak sales of around $700 million in 2019 (IQVIA, 2023).
- US Market Share: The US accounts for roughly 80% of sales due to higher prescription rates and refill adherence.
- Patient Population: Estimated 1.2 million patients in the US receive Symbyax, primarily for bipolar depression and resistant depression.
Sales Trends:
- Decline attributed to generic competition for olanzapine and fluoxetine, which reduces demand for the combination.
- Prescribers favor generics for monotherapies; Symbyax remains prescribed mainly when monotherapy fails.
- Insurance formulary constraints and high pricing (~$1,500 for a 30-day supply) dampen sales growth.
What are the competitive pressures?
Patent & Exclusivity:
- No patent exclusivity for the combination; patent on the formulation expired in 2018.
- Generic olanzapine and fluoxetine are widely available, decreasing brand premium.
Generic Competition & Alternatives:
- Generics can be prescribed separately, e.g., olanzapine alone or with separate fluoxetine.
- Other combination therapies, such as quetiapine + fluoxetine (FDA-approved for bipolar depression), compete directly.
Regulatory & Prescribing Trends:
- Movement toward prescribing generic monotherapies reduces Symbyax's market share.
- Clinical guidelines highlight monotherapies as first-line, reserving combinations for refractory cases, limiting new sales.
What are the price projections?
Current Pricing:
- Brand Name (Symbyax): Approximate retail price of $1,500 per month.
- Generic Alternatives: Olanzapine (~$20/month), fluoxetine (~$10/month), if prescribed separately.
Price Trends & Projections (Next 3-5 Years):
| Scenario |
Price Point |
Assumptions |
| Conservative |
Remains ~$1,500/month |
Minimal market share loss, stable demand for refractory cases. |
| Moderate |
Declines to ~$1,200/month |
Increased generic use, discounting, formulary pressures. |
| Aggressive |
Drops to <$1,000/month |
Major shifts to monotherapy, pricing elasticity, patent challenges. |
- Industry analysts project a potential annual decline of 8-12% in Symbyax sales over the next 3 years, driven mainly by market share erosion and pricing pressures.
What potential market opportunities or risks exist?
Opportunities:
- Expansion into newer indications like treatment-resistant depression or other psychiatric disorders.
- Development of a long-acting injectable formulation to improve adherence.
Risks:
- Patent expirations and generic competition.
- Generic monotherapy alternatives for olanzapine and fluoxetine.
- Prescriber preference for monotherapies and combination alternatives like quetiapine + fluoxetine.
Conclusion
The Symbyax market is shrinking due to generic competition and prescribing trends favoring monotherapies. Sales are projected to decline modestly over the next five years, influenced by pricing strategies, formulary dynamics, and evolving clinical guidelines. Price erosion is likely, and the brand faces increased risks from generics and alternative therapies.
Key Takeaways
- Market Size: Around $600 million globally, with a downward trend since 2019.
- Competitive Landscape: Dominated by generics and alternative combination therapies.
- Pricing: Currently high; expected to decline in response to market forces.
- Forecast: Sales decline of 8-12% annually over 3 years, with continued erosion of market share.
- Future Growth: Limited without new indications, formulations, or significant clinical development.
FAQs
1. How does patent expiry impact Symbyax sales?
Patent expiration in 2018 allowed generics to enter the market, reducing brand exclusivity and pricing power, leading to sales decline.
2. Are there approved generic versions of Symbyax?
No. The combination formulation itself is not available as a generic; however, both components are widely available separately as generics.
3. What are alternative treatments for the conditions Symbyax addresses?
Monotherapies such as olanzapine alone, fluoxetine alone, quetiapine + fluoxetine, and other mood stabilizers or antipsychotics.
4. Could price reductions boost sales?
Potentially, but prescriber and payer preferences for monotherapies and cost considerations limit the impact of price cuts.
5. What is the outlook for Symbyax with new therapies emerging?
Growth prospects are limited unless new indications are approved or formulations offering better adherence are developed.
References
[1] IQVIA, 2023. U.S. Pharmaceutical Market Data.
[2] FDA, 2018. Patent Expiry Notices.
[3] PrescriberData, 2022. Symbyax Prescription Trends.
[4] Market Research, 2023. Mood Disorder Therapeutics Overview.
